After Failed IVF Abroad: What U.S. Patients Should Ask Clinics Before Shipping Embryos, Reviewing PGT Results, or Starting a New Cycle

A failed IVF cycle abroad can leave U.S. patients with a difficult mix of emotions and practical questions: Was the embryo truly viable? Were the genetic testing results interpreted correctly? Should the remaining embryos be shipped back to the United States? Is it safer to start over at home? Before making a fast decision, patients should slow down, collect records, and ask very specific questions of any U.S. fertility clinic they are considering. The goal is not to assign blame, but to understand what happened, protect any remaining embryos, and design a more informed next step.

1. First, clarify what “failed IVF abroad” actually means

Patients often use the phrase “failed IVF” to describe very different situations. A U.S. clinic should begin by defining the exact point at which the cycle was unsuccessful. Did stimulation produce too few eggs? Were eggs retrieved but not mature? Did fertilization fail? Did embryos arrest before blastocyst stage? Were embryos genetically abnormal on preimplantation genetic testing? Did a euploid embryo transfer fail to implant? Was there a biochemical pregnancy, miscarriage, or ectopic pregnancy?

Each scenario points toward different questions. For example, if few eggs were retrieved, the next conversation may focus on ovarian reserve, stimulation protocol, medication dosing, trigger timing, or whether a mild stimulation approach was chosen. If many mature eggs fertilized but embryos stopped growing, the review may focus on egg quality, sperm DNA fragmentation, culture conditions, and lab performance. If a tested euploid embryo failed to implant, the evaluation may shift toward uterine cavity assessment, transfer technique, endometrial preparation, thrombophilia or endocrine factors, and whether the PGT result is reliable.

Before shipping embryos or starting another cycle, ask the new clinic to explain which category your prior outcome belongs to. A well-organized clinic should be able to review your history and say, “Your main issue appears to be low oocyte yield,” or “Your embryo development was unexpectedly poor,” or “The key question is why a euploid transfer did not lead to an ongoing pregnancy.” Without this clarity, patients may repeat an expensive cycle without changing the variables that matter.

2. Bring complete records, not just a summary email

International IVF care often involves multiple languages, different laboratory reporting formats, and variable record-keeping standards. A short message saying “three embryos were normal” or “the transfer failed” is not enough for medical decision-making in the United States. Patients should request a full copy of the medical and embryology file from the overseas clinic before the consultation.

If the records are not in English, ask whether the U.S. clinic requires certified translation. For genetic and embryology reports, informal translation can introduce dangerous errors. Terms such as “mosaic,” “chaotic,” “segmental,” “low-level mosaic,” and “no result” may have specific clinical meaning.

3. Questions to ask before shipping embryos to the United States

Shipping embryos internationally is possible in many circumstances, but it is not as simple as sending a package. Embryos are cryopreserved biological material, and transport requires legal consent, chain-of-custody documentation, proper identification, validated cryoshipping equipment, customs clearance, and coordination between the sending and receiving laboratories. Some U.S. clinics are comfortable receiving embryos from abroad; others accept them only from certain countries or only if documentation meets strict standards.

Before paying for transport, ask the U.S. clinic whether it will accept the embryos and under what conditions. Do not assume that because embryos exist abroad, they can automatically be used in a U.S. laboratory. The receiving clinic may require infectious disease testing, identity verification, consent forms from both partners or gamete providers, documentation of ownership, and confirmation of the freezing method.

Key questions for the receiving U.S. clinic

• Do you accept embryos created and frozen outside the United States? If yes, from which countries and under what conditions?
• What documentation must the foreign clinic provide? Ask for a written checklist.
• Do you require infectious disease screening for the patients, sperm provider, egg provider, or gestational carrier? Requirements may vary depending on how the embryos were created and how they will be used.
• Will your lab accept embryos frozen by vitrification, slow-freezing, or an unknown method? Most modern embryos are vitrified, but older or incomplete records can complicate warming.
• Do you require information about the cryo device? The receiving lab may need to know whether embryos are stored in straws, Cryotops, Cryolocks, CBS devices, or other carriers.
• How many embryos are on each device? If multiple embryos are stored together, warming one may require warming others.
• Can your laboratory warm embryos frozen on the specific carrier used abroad? Experience with the exact device can matter.
• Who coordinates the chain of custody? Clarify responsibilities among the patient, foreign clinic, courier, and U.S. clinic.
• What happens if embryos arrive with incomplete or mismatched labels? Ask about the clinic’s policy before shipment.
• What are the risks of transport? The risk is usually low with professional cryoshipping, but no transport is risk-free.

Patients should also ask whether the U.S. clinic uses a preferred specialized reproductive tissue courier. A professional cryoshipper is charged with liquid nitrogen vapor, validated for temperature maintenance, sealed, tracked, and handled according to procedures for biological reproductive material. General shipping services may not be appropriate. Patients should ask how long the tank remains within safe temperature range, whether a temperature logger is used, what insurance is available, and who is responsible if customs delays occur.

Embryo shipping also raises legal and consent issues. If embryos were created with donor eggs, donor sperm, a partner’s sperm, or as part of a surrogacy arrangement, documentation may be more complex. U.S. clinics may require proof that the people requesting shipment have legal authority to direct embryo disposition. If a relationship has ended, one partner may not be able to move or use embryos without the other’s consent. If the embryos were created using anonymous donors abroad, donor eligibility documentation may be different from U.S. standards.

4. Understand that PGT results from abroad may need reinterpretation

Preimplantation genetic testing is a powerful tool, but it is not a simple “good embryo versus bad embryo” label. PGT results depend on biopsy technique, embryo stage, the number of cells sampled, DNA amplification, testing platform, laboratory thresholds, bioinformatics, reporting style, and clinic policy. Different countries and laboratories may classify embryos differently. One lab may call an embryo “mosaic,” another may call it “abnormal,” and another may issue a “no result” or “inconclusive” category.

U.S. patients should ask whether the receiving clinic has a genetic counselor or reproductive genetics specialist who can review the original PGT report. Ideally, the review should include the type of testing performed: PGT-A for aneuploidy, PGT-M for a monogenic disease, PGT-SR for structural rearrangements, or a combination. Patients should not assume that “PGT normal” means the embryo was tested for all genetic conditions. PGT-A screens chromosome copy number; it does not rule out most single-gene disorders, microdeletions below the platform’s resolution, autism, many birth defects, or all causes of miscarriage.

Questions to ask when reviewing PGT reports

• Which laboratory performed the testing? Ask for the full report, not a screenshot or verbal summary.
• What technology was used? Common platforms include next-generation sequencing, array CGH, SNP array, or other methods.
• Was the embryo biopsy performed at cleavage stage or blastocyst stage? Most modern PGT-A uses trophectoderm biopsy from blastocysts.
• What does the report call each embryo: euploid, aneuploid, mosaic, segmental aneuploid, complex abnormal, chaotic, or no result?
• Were mosaic thresholds reported? For example, some labs report low-level and high-level mosaicism using percentage ranges.
• Were sex chromosomes reported, and do we want to know that information? Patients should understand the clinic’s policies and state laws.
• Was PGT-M performed with a custom probe or family-specific workup? If there is a known genetic disease, documentation is critical.
• Can the embryo be retested if the result is inconclusive? Retesting requires thawing, rebiopsy, and refreezing, which may reduce viability.
• Would your clinic transfer a mosaic embryo from this report? Policies vary significantly.
• What prenatal testing would be recommended after pregnancy? PGT reduces risk but does not replace prenatal screening or diagnostic testing.

Mosaic embryo decisions deserve special caution. A mosaic result means the biopsy sample showed a mixture of apparently normal and abnormal cells, or an intermediate chromosomal signal suggesting such a mixture. Some mosaic embryos can lead to healthy live births, but outcomes depend on the chromosome involved, the level of mosaicism, whether the abnormality is whole-chromosome or segmental, and the clinic’s experience. Patients should ask for counseling about implantation rates, miscarriage risk, possible fetal or placental mosaicism, and recommended prenatal follow-up such as chorionic villus sampling or amniocentesis. These decisions should be individualized, not made from a generic internet chart.

Patients should also understand the limits of PGT-A after a failed transfer. A euploid embryo that does not implant may still have had biological limitations not detected by PGT-A, including mitochondrial issues, epigenetic problems, embryo-endometrium asynchrony, or damage during warming. Conversely, a failed transfer does not prove the PGT result was wrong. The review should be balanced and scientific.

5. Ask the U.S. clinic to review embryo quality beyond genetics

Genetic testing is only one part of embryo assessment. Morphology, developmental timing, biopsy day, expansion grade, inner cell mass quality, trophectoderm quality, cryopreservation method, and post-warming survival all matter. A day-5 4AA euploid blastocyst and a day-7 5CC euploid blastocyst may both be “normal” genetically, but their expected implantation potential can differ.

Ask the clinic to review the embryo grading system used abroad. Not every laboratory grades embryos exactly the same way. Some reports use Gardner grading; others use local scoring systems. If photographs or time-lapse videos are available, ask whether the embryology team can review them. This does not guarantee a different conclusion, but it may provide context.

Important questions include: On what day were the embryos biopsied and frozen? Were they fully expanded blastocysts? Were any embryos frozen at cleavage stage? Were embryos collapsed before vitrification? What was the survival rate after thawing in the previous cycle? Did the embryo re-expand before transfer? Was assisted hatching performed? If the failed cycle involved a frozen embryo transfer abroad, these details can help determine whether the embryo looked viable at the time of transfer.

6. Evaluate whether the uterus was fully assessed before transfer

When a transfer fails, patients often focus on embryos, but the uterus deserves equal attention. A normal ultrasound is reassuring but may not detect all intrauterine problems. Polyps, submucosal fibroids, adhesions, septum, chronic endometritis, hydrosalpinx, adenomyosis, and fluid in the cavity can reduce implantation or increase miscarriage risk. Before another transfer, especially after a failed euploid transfer, ask whether additional uterine evaluation is appropriate.

Common tools include saline infusion sonography, hysteroscopy, high-quality transvaginal ultrasound, MRI when adenomyosis or complex fibroids are suspected, and endometrial biopsy in selected cases. Hysteroscopy allows direct visualization of the uterine cavity and treatment of certain abnormalities. Saline sonogram is less invasive and can detect many cavity lesions. There is no single test required for everyone; the right approach depends on history, prior imaging, symptoms, and embryo availability.

Ask the clinic: Was my uterine cavity assessed within the last 6 to 12 months? Do I have fibroids, polyps, scar tissue, or signs of adenomyosis? Should I be evaluated for hydrosalpinx if I have tubal disease? If I had a miscarriage or prior uterine surgery, should we consider hysteroscopy? If I had recurrent implantation failure, what evidence-based tests do you recommend and which tests do you not recommend?

7. Review the frozen embryo transfer protocol carefully

A failed transfer may relate to embryo factors, uterine factors, or protocol timing. Frozen embryo transfer can be performed in a programmed cycle, a natural ovulatory cycle, or a modified natural cycle. Each has advantages and disadvantages. A programmed cycle uses estrogen and progesterone to prepare the lining and does not require ovulation. A natural or modified natural cycle relies on the patient’s own ovulation and corpus luteum, sometimes with trigger medication and progesterone support.

Patients should ask what protocol was used abroad and whether the U.S. clinic would recommend the same approach. In a programmed cycle, progesterone exposure timing is critical. Too little or too much progesterone before transfer can shift the implantation window. Ask when progesterone started, what route was used, whether levels were checked, and whether the transfer timing matched the embryo stage. For example, a day-5 blastocyst is typically transferred after an appropriate duration of progesterone exposure, but exact protocols vary.

Ask about endometrial thickness and pattern, estradiol level, progesterone level before starting progesterone, progesterone level near transfer, luteal support, and whether there were symptoms such as bleeding before transfer. If injectable progesterone was not used, ask whether vaginal progesterone absorption might have been a concern. If a natural cycle was used, ask how ovulation was confirmed and how timing was calculated.

8. Do not ignore sperm factors after embryo arrest or poor blastocyst development

Many patients assume IVF outcome is mostly about egg age, but sperm quality can affect fertilization, embryo development, miscarriage risk, and potentially blastocyst formation. Standard semen analysis measures volume, concentration, motility, and morphology, but it does not evaluate every function. If a cycle abroad showed poor fertilization, low blastocyst development, unexpected embryo arrest, or recurrent miscarriage, the U.S. clinic may recommend a more detailed male-factor evaluation.

Questions to ask include: Was ICSI used? Was fertilization normal? Were there many abnormal fertilized eggs? Has the male partner had a recent semen analysis? Should sperm DNA fragmentation testing be considered? Are there lifestyle factors, heat exposure, medications, testosterone use, varicocele, infections, or medical conditions that should be addressed? Should a reproductive urologist be involved?

Sperm DNA fragmentation testing is not necessary for every patient, and results do not always change management. However, in selected cases, it may support interventions such as treating varicocele, changing lifestyle factors, shortening abstinence interval, using testicular sperm in severe cases, or optimizing lab techniques. The important point is to ask whether sperm factors were adequately considered rather than assuming the next cycle should simply use the same sperm approach.

9. Reassess ovarian reserve and stimulation strategy before starting over

If no usable embryos remain or if shipping is not practical, starting a new IVF cycle in the United States may be reasonable. Before doing so, the U.S. clinic should reassess ovarian reserve, prior response, age-related prognosis, and the stimulation plan. Ovarian reserve tests often include AMH, antral follicle count, day-2 or day-3 FSH and estradiol, and review of prior stimulation response. These tests do not determine whether a patient can have a baby with absolute certainty, but they help estimate expected egg yield and guide dosing.

Ask what the clinic learned from the overseas cycle. Did the number of eggs retrieved match the antral follicle count? Was the maturity rate low? Was there a high proportion of immature eggs? Was the trigger medication appropriate? Was dual trigger considered? Did follicle sizes at trigger suggest asynchronous growth? Was the stimulation too aggressive or too mild? Would priming with estrogen, oral contraceptives, or androgen support be useful, or could it suppress response? Would a microdose flare, antagonist, long agonist, or mild stimulation protocol be more appropriate?

Patients with diminished ovarian reserve should ask about realistic expectations. A clinic should be honest about the likely number of eggs, embryos, and euploid embryos per cycle based on age and prior response. Patients should also ask whether embryo banking over multiple cycles is recommended, whether fresh transfer is ever considered, and whether donor eggs should be discussed as an option. Discussing donor eggs does not mean giving up; it means understanding the full reproductive landscape.

10. Compare success rates carefully and ethically

After a failed cycle abroad, patients may be vulnerable to clinics that promise unusually high success rates. In the United States, fertility clinics report outcomes through systems such as SART and CDC reporting, but even these numbers require careful interpretation. Success rates depend on patient age, diagnosis, use of donor eggs, number of embryos transferred, PGT use, embryo banking, cancellation policies, and whether the denominator is retrieval, transfer, or patient.

Ask the clinic for success rates relevant to your situation: your age group, your diagnosis, your own eggs or donor eggs, frozen euploid transfer if applicable, and prior failed cycle history. Ask for live birth rate, not only positive pregnancy rate. Ask how the clinic counsels about single embryo transfer and multiple pregnancy risk. A clinic that transfers multiple embryos to inflate pregnancy rates may increase twin or higher-order pregnancy risks, which can be dangerous for both mother and babies.

Patients should also ask how the clinic handles difficult-prognosis cases. Some clinics may have high success rates partly because they discourage patients with lower prognosis from starting treatment. A lower published success rate does not automatically mean poor care, and a higher rate does not guarantee success for an individual. Look for transparent counseling, careful lab standards, and individualized planning.

11. Ask about laboratory quality and communication

The embryology laboratory is central to IVF success. Patients rarely meet the embryologists, but they should feel comfortable asking about lab quality. A strong laboratory should have validated protocols, quality control, equipment monitoring, air quality systems, temperature and pH control, witness systems, and clear identification procedures. In the U.S., labs may be accredited or inspected through relevant regulatory and professional bodies, but patients should still ask practical questions.

Ask whether the lab uses electronic witnessing or double-witness procedures to prevent specimen mix-ups. Ask how incubators are monitored, whether embryos are cultured individually or in groups, whether time-lapse incubators are used, and how biopsy and vitrification are performed. Not every advanced technology improves outcomes for every patient, but the clinic should be able to explain its methods clearly.

Communication matters as much as technology. Patients coming from international treatment often felt confused because they received minimal updates or reports in another language. Ask the U.S. clinic how often you will receive updates after retrieval, who explains fertilization and blastocyst results, how PGT results are delivered, and whether you can speak with a genetic counselor. Clarity reduces anxiety and helps patients make informed decisions.

12. Consider infectious disease, donor, and FDA-related documentation

U.S. fertility clinics operate within a regulatory environment that includes requirements for human cells, tissues, and cellular and tissue-based products. The details can be complex, especially when embryos were created abroad, with donor gametes, or intended for use with a gestational carrier. Patients do not need to become regulatory experts, but they should understand that missing infectious disease or donor eligibility documentation can affect whether and how embryos may be used.

If embryos were created using the patient’s own eggs and partner sperm for use by the same couple, requirements may differ from embryos created with donor eggs, donor sperm, or donor embryos. If a gestational carrier will carry the pregnancy, clinics may apply additional screening and documentation standards. International donor screening may not match U.S. requirements in timing, test type, or documentation.

Ask the clinic: Are my embryos eligible for transfer at your center? If donor gametes were used, do we have sufficient donor screening records? If records are incomplete, can the embryos still be used with appropriate labeling and informed consent, or not at all? If we plan to use a gestational carrier, are there additional requirements? These questions should be answered before paying for embryo shipment.

13. Review financial risks before committing

Failed IVF abroad is often financially stressful because many patients traveled internationally to reduce cost. Returning to U.S. care may involve higher expenses, but it may also offer easier monitoring, clearer communication, and stronger continuity. Before making decisions, ask for a written estimate that separates consultation, record review, embryo import, storage, lab receiving fee, embryo warming, transfer, monitoring, medications, PGT review, additional testing, and possible repeat IVF.

Patients should ask whether insurance covers any part of care. Some plans cover diagnostic testing but not IVF. Others cover IVF but not PGT, embryo storage, donor services, or international shipping. Medication benefits may be separate from medical benefits. Ask the clinic’s financial counselor to provide billing codes when possible and to clarify refund policies if embryos cannot be accepted after review.

Also compare the cost of shipping existing embryos versus creating new embryos. If embryos abroad are euploid and well documented, shipping may be the most efficient option. If embryos have uncertain identity documentation, unclear PGT results, poor-quality freezing records, or legal consent problems, starting a new cycle may be safer despite higher upfront cost. This is a medical, emotional, legal, and financial decision.

14. Ask whether additional tests are evidence-based

After IVF failure, patients are often offered many add-on tests: immune panels, natural killer cell testing, endometrial receptivity assays, microbiome testing, thrombophilia panels, empiric blood thinners, intralipids, steroids, platelet-rich plasma, growth hormone, and more. Some may be appropriate in selected cases; many remain controversial or lack strong evidence for routine use.

A trustworthy clinic should be willing to say, “This test is not proven for your situation,” or “This may be considered, but the evidence is limited.” Ask what management would change based on the result. If a test does not change treatment, it may not be useful. If a treatment has potential risks, such as immune suppression, bleeding, mood effects, or metabolic effects, those risks should be discussed.

Reasonable evaluation after failed IVF often starts with fundamentals: confirming embryo status, reviewing lab data, checking uterine cavity, optimizing endocrine health, evaluating sperm factors when indicated, and ensuring transfer timing. Add-ons should not replace a careful review of basic clinical and embryology details.

15. Prepare emotionally and medically for the next consultation

Patients frequently arrive after overseas IVF feeling disappointed, embarrassed, or mistrustful. Some worry they made a mistake by traveling abroad. Others feel pressured by age, finances, or family expectations. A good fertility team should meet patients with compassion and facts. The consultation should include enough time to review prior records, discuss prognosis, and compare options without rushing toward a new cycle.

Before the appointment, write down your top goals. Is your priority to use remaining embryos if possible? To understand why the transfer failed? To avoid repeating the same protocol? To reduce miscarriage risk? To minimize cost? To move quickly because of age? To consider donor eggs or surrogacy? Clear goals help the physician tailor recommendations.

Patients should also prepare a reproductive timeline: age, pregnancies, miscarriages, surgeries, diagnoses, prior treatments, stimulation details, number of eggs retrieved, embryos created, PGT results, transfers, medications, and outcomes. Include male partner or sperm source history when relevant. The more complete the timeline, the more productive the consultation.

16. A practical checklist for U.S. patients after failed IVF abroad

17. Red flags when choosing a clinic after an overseas IVF failure

Patients should be cautious if a clinic promises success without reviewing records, dismisses the overseas clinic automatically, insists on expensive add-ons without explanation, refuses to provide written costs, or cannot explain its embryo import requirements. Another red flag is pressure to ship embryos immediately before the laboratory has reviewed documentation. Similarly, a clinic should not recommend discarding embryos based only on a vague report or non-expert interpretation of PGT.

Be careful with any provider who guarantees that a specific protocol, supplement, immune treatment, or receptivity test will solve the problem. IVF medicine is probabilistic. Good care improves the odds by identifying modifiable factors, but it cannot eliminate biological uncertainty. Patients deserve hope, but hope should be built on accurate information.

18. When shipping embryos may be reasonable—and when starting over may be better

Shipping embryos may be reasonable when the embryos are clearly identified, legally transferable, properly documented, frozen by a method the U.S. lab can handle, and accompanied by reliable embryology and PGT reports. It may be especially worthwhile if the embryos are euploid, created at a younger maternal age, or represent the patient’s only remaining embryos.

Starting a new cycle may be more reasonable when embryo documentation is incomplete, legal consent is uncertain, PGT results are unreliable or unavailable, embryo quality is poor, transport is not feasible, or the patient wants care under a U.S. laboratory from stimulation through transfer. Some patients choose both: shipping existing embryos while planning a new retrieval, especially if age or ovarian reserve makes time important.

There is no universal answer. The best decision depends on embryo quality, patient age, medical history, prognosis, finances, emotional readiness, and legal details. A good U.S. clinic should present options with pros and cons rather than pushing a single path.

19. Final perspective from a reproductive medicine standpoint

A failed IVF cycle abroad is not the end of the road, and it is not a diagnosis by itself. It is a data point. The most important next step is to transform that data into a plan. For some patients, the right plan is to ship embryos safely, reinterpret PGT results, optimize the uterus, and proceed with a carefully timed frozen embryo transfer. For others, the right plan is to repeat IVF with a different stimulation strategy, deeper sperm evaluation, improved lab communication, or donor options. For some, the best first step is simply to pause, gather records, and receive counseling before making another major decision.

U.S. patients should ask clinics to be specific: What do you need before accepting my embryos? How do you interpret my PGT report? What do you think caused the prior failure? What would you change? What would you keep the same? What are the risks, costs, and alternatives? These questions help patients move from uncertainty to informed decision-making.